{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:36:52Z","timestamp":1792316212760,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.ctrv.2009.04.002","type":"journal-article","created":{"date-parts":[[2009,9,17]],"date-time":"2009-09-17T09:15:48Z","timestamp":1253178948000},"page":"503-508","source":"Crossref","is-referenced-by-count":36,"title":["Management of primary and advanced breast cancer in older unfit patients (medical treatment)"],"prefix":"10.1016","volume":"35","author":[{"given":"M.","family":"Aapro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Monfardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2009.04.002_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2009.04.002_bib2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/annonc\/mdm593","article-title":"Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations","volume":"19","author":"H\u00e9ry","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib3","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1200\/JCO.2003.02.046","article-title":"Undertreatment strongly decreases prognosis of breast cancer in elderly women","volume":"21","author":"Bouchardy Bouchardy","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/14737140.4.2.197","article-title":"Treatment options for early breast cancer in elderly women","volume":"4","author":"Basso","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2009.04.002_bib5","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2005.02.3028","article-title":"Use and outcomes of adjuvant chemotherapy in older women with breast cancer","volume":"24","author":"Giordano","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.285.7.885","article-title":"Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older","volume":"285","author":"Yancik","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2009.04.002_bib7","unstructured":"Ries LAG, Harkins D, Krapcho M, et al. Cancer statistics review 1975_2003. Bethesda: National Cancer Institute. Available from: http:\/\/seer.cancer.gov\/csr\/1975_2003\/ [accessed February 2009]."},{"key":"10.1016\/j.ctrv.2009.04.002_bib8","first-page":"221","article-title":"General guidelines for the management of older patients with cancer","volume":"14","author":"Balducci","year":"2000","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/j.ctrv.2009.04.002_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2007.12.006","article-title":"Management of frail and not-frail elderly cancer patients in a hospital-based geriatric oncology program","volume":"66","author":"Basso","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1040-8428(03)00099-4","article-title":"A comprehensive geriatric intervention detects multiple problems in older breast cancer patients","volume":"49","author":"Exterman","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1634\/theoncologist.10-3-198","article-title":"Never too old? Age should not be a barrier to enrollment in cancer clinical trials","volume":"10","author":"Aapro","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2009.04.002_bib12","first-page":"CD004272","article-title":"Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)","author":"Hind","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2009.04.002_bib13","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.ejca.2007.07.007","article-title":"Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients \u2013 a jungle?","volume":"43","author":"Biganzoli","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2009.04.002_bib14","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2003.03.559","article-title":"International Breast Cancer Study Group. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV","volume":"21","author":"Crivellari","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib15","first-page":"24","article-title":"Comorbidity and choice of adjuvant endocrine therapy in breast cancer patients (pts) older than 70 years","author":"Monfardini","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/15622970309167955","article-title":"Antidepressant drugs in the elderly \u2013 role of the cytochrome P450 2D6","volume":"4","author":"Vandel","year":"2003","journal-title":"World J Biol Psychiatr"},{"key":"10.1016\/j.ctrv.2009.04.002_bib17","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","article-title":"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Jin","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2009.04.002_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjc.6604533","article-title":"Tamoxifen\u2019s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram","volume":"99","author":"Lash","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2009.04.002_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ctrv.2007.11.001","article-title":"Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review","volume":"34","author":"Eisen","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2009.04.002_bib21","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1200\/JCO.2007.14.0459","article-title":"Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial","volume":"26","author":"Crivellari","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib22","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.2007.12.6334","article-title":"Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17","volume":"26","author":"Muss","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(06)70948-2","article-title":"Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis","volume":"7","author":"Jonat","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2009.04.002_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib26","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib27","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1200\/JCO.2000.18.8.1709","article-title":"What threshold for adjuvant therapy in older breast cancer patients?","volume":"18","author":"Extermann","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib28","unstructured":"www.adjuvantonline.com [accessed February 2009]."},{"key":"10.1016\/j.ctrv.2009.04.002_bib29","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/annonc\/mdi257","article-title":"Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients","volume":"16","author":"Brunello","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(08)60069-0","article-title":"Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials","volume":"371","author":"Clarke","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2009.04.002_bib31","first-page":"26","author":"Muss","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib32","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2000.18.7.1412","article-title":"Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII","volume":"18","author":"Crivellari","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(07)70378-9","article-title":"International Society of Geriatric Oncology. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology","volume":"8","author":"Wildiers","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib34","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2009.04.002_bib35","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1634\/theoncologist.2008-0001","article-title":"Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Dahabreh","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2009.04.002_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemo therapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2009.04.002_bib37","unstructured":"Clemens M, Kaufman JR, Mackey P, et al. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: results of a post-hoc analysis from the TAnDEM study. American Society of Clinical Oncology Breast Cancer Symposium; 2007 [abstr. 231]."},{"issue":"6","key":"10.1016\/j.ctrv.2009.04.002_bib38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000090985","article-title":"Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer","volume":"69","author":"Bertelli","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2009.04.002_bib39","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2005.04.5773","article-title":"Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients","volume":"24","author":"Bottini","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib40","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib41","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3816\/CBC.2008.n.040","article-title":"Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer","volume":"8","author":"McCormack","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2009.04.002_bib43","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.ejca.2007.03.017","article-title":"Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy","volume":"43","author":"Hamberg","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2009.04.002_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/157489208786242313","article-title":"Chemotherapy and targeted agents for elderly women with advanced breast cancer","volume":"3","author":"Brunello","year":"2008","journal-title":"Recent Pat Anti-Cancer Drug Discov"},{"key":"10.1016\/j.ctrv.2009.04.002_bib45","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1200\/JCO.2005.02.167","article-title":"Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women","volume":"23","author":"Bajetta","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2009.04.002_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/00003495-200767050-00002","article-title":"Oral vinorelbine: role in the management of metastatic breast cancer","volume":"67","author":"Aapro","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2009.04.002_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2009.04.002_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00002512-200724050-00004","article-title":"Oral anticancer drugs in the elderly: an overview","volume":"24","author":"Lonardi","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ctrv.2009.04.002_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.critrevonc.2007.12.008","article-title":"A significant proportion of elderly patients develop hormone-dependant \u201cluminal-B\u201d tumours associated with aggressive characteristics","volume":"67","author":"Durbecq","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1634\/theoncologist.2007-0204","article-title":"Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer","volume":"13","author":"Bullock","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2009.04.002_bib51","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdl476","article-title":"Review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer","volume":"18","author":"Chan","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib52","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.2007.11.9776","article-title":"Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer","volume":"25","author":"Bartsch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib53","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/S0959-8049(01)81184-9","article-title":"Older (age >60) patients obtain survival benefit from herceptin plus chemotherapy","volume":"37","author":"Fyfe","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2009.04.002_bib54","first-page":"26","article-title":"Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (>70 years)","author":"Brunello","year":"2008","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib55","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2009.04.002_bib56","first-page":"17S","article-title":"Can bevacizumab be safely administered to all coorectal cancer (CRC) patients older than 70 years?","author":"Pasetto","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib57","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","article-title":"International Society of Geriatric Oncology. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients","volume":"43","author":"Body","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2009.04.002_bib58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2009.04.002_bib59","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2354.2004.00551.x","article-title":"Multidimensional geriatric evaluation in elderly cancer patients: a practical approach","volume":"13","author":"Basso","year":"2004","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ctrv.2009.04.002_bib60","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ejca.2008.01.002","article-title":"Vulnerable and frail elderly: an approach to the management of the main tumour types","volume":"44","author":"Monfardini","year":"2008","journal-title":"Eur J Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737209000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737209000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T17:45:59Z","timestamp":1558547159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737209000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0305737209000607"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2009.04.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}